Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06209606 · ClinicalTrials.gov registry record · Early Phase 1

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

A Early Phase 1 study of Multiple Myeloma, sponsored by Oncotherapeutics.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT06209606 is a Early Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Oncotherapeutics. The registered enrollment target is 30 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06209606, a Early Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Oncotherapeutics.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Lenalidomide
  • DRUG Methylprednisolone
  • DRUG Ruxolitinib Oral Tablet [Jakafi]

Study Locations (1)

California

  • Berenson Cancer Center - West Hollywood

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-12-08
Est. Completion 2029-02
Phase Early Phase 1

Sponsor

Oncotherapeutics

17 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06209606

The ClinicalTrials.gov registry entry for NCT06209606 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is Oncotherapeutics, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.

NCT06209606 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06209606 about?

NCT06209606 is a clinical study titled "Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma". This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.

What is the current status of trial NCT06209606?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2022-12-08. Estimated completion is 2029-02.

What conditions does trial NCT06209606 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06209606?

The interventions under investigation include: Lenalidomide (DRUG), Methylprednisolone (DRUG), Ruxolitinib Oral Tablet [Jakafi] (DRUG).

Who is sponsoring clinical trial NCT06209606?

This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06209606 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.